- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Donor-specific antibody.
Displaying page 1 of 2.
EudraCT Number: 2013-004956-39 | Sponsor Protocol Number: SMART-DSA | Start Date*: 2014-06-18 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population | |||||||||||||
Medical condition: Renal Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000027-14 | Sponsor Protocol Number: T-19-11318v19 | Start Date*: 2018-08-20 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation | |||||||||||||
Medical condition: Chronic active antibody mediated rejection of renal transplants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002882-20 | Sponsor Protocol Number: | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transpla... | |||||||||||||
Medical condition: Renal Transplant antibody-mediated rejection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000322-66 | Sponsor Protocol Number: CRAD001A2433 | Start Date*: 2013-11-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi... | |||||||||||||
Medical condition: Adult kidney transplant recipients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001854-24 | Sponsor Protocol Number: NL67751.078.18 | Start Date*: 2019-08-07 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus. Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a ... | ||
Medical condition: kidney transplantation vaccination responses | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002064-13 | Sponsor Protocol Number: 15-HMedIdeS-06 | Start Date*: 2016-10-05 |
Sponsor Name:Hansa Medical AB | ||
Full Title: A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test | ||
Medical condition: Chronic Kidney Disease with donor specific antibodies (ASA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000022-66 | Sponsor Protocol Number: 16-HMedIdeS-12 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Hansa Medical AB | |||||||||||||
Full Title: A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibod... | |||||||||||||
Medical condition: Antibody-mediated rejection in kidney transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004137-27 | Sponsor Protocol Number: ScanCLAD_1.0(formerVersion_0.1) | Start Date*: 2016-05-19 |
Sponsor Name:Transplantationscentrum, Sahlgrenska Universitetssjukhuset | ||
Full Title: A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysf... | ||
Medical condition: Recipients of primary bilateral lung transplant allograft | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001604-30 | Sponsor Protocol Number: 1001 | Start Date*: 2017-12-11 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial | ||
Medical condition: Antibody-mediated rejection of a kidney transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000237-12 | Sponsor Protocol Number: IM103-402 | Start Date*: 2021-05-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a... | |||||||||||||
Medical condition: Adolescent Renal Allografts | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000419-56 | Sponsor Protocol Number: TCD601B101 | Start Date*: 2021-03-23 | |||||||||||
Sponsor Name:ITB-MED AB | |||||||||||||
Full Title: A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (si... | |||||||||||||
Medical condition: renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000348-17 | Sponsor Protocol Number: CSL842_3001 | Start Date*: 2017-11-17 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of ... | |||||||||||||
Medical condition: Refractory AMR in adult renal transplant participants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000695-15 | Sponsor Protocol Number: 6997 | Start Date*: 2020-12-15 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
Full Title: Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing Antibody Titers at the day of transplantation: A Multicente... | ||
Medical condition: Kidney Transplantation BKV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003254-24 | Sponsor Protocol Number: | Start Date*: 2019-07-03 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: AGe-adapted benefits of Envarsus versus twice-daily tacrolimus ImmunosuppressioN druGs after kidney transplantation (AGEING) – a feasibility study | ||
Medical condition: Immunosuppression in Renal transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000561-33 | Sponsor Protocol Number: TOL-2 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:TolerogenixX GmbH | |||||||||||||
Full Title: An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-ca... | |||||||||||||
Medical condition: Living donor kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002643-18 | Sponsor Protocol Number: REDUCE | Start Date*: 2018-09-04 | |||||||||||||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||||||||||||
Full Title: REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosu... | |||||||||||||||||||||||
Medical condition: Immunosuppression after kidney transplantion in elderly patients ≥65 years of age | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000441-12 | Sponsor Protocol Number: 0624-201 | Start Date*: 2012-09-21 | |||||||||||
Sponsor Name:VIROPHARMA Incorporated | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled pilot study to evaluate the safety and effect of Cinryze (C1 Esterase Inhibitor (Human)) for the treatment of acute antibody-mediated rejection in rec... | |||||||||||||
Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000652-18 | Sponsor Protocol Number: 18IC4423 | Start Date*: 2018-07-27 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Study to compare once-daily Extended Release Tacrolimus Versus twice-daily Immediate Release Tacrolimus following renal allograft failure to Reduce the risk of Allosensitisation | |||||||||||||
Medical condition: Transplant rejection following transplant failure and return to dialysis (transplant rejection defined as the development of new HLA antibodies against the transplant) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003867-79 | Sponsor Protocol Number: IDTX-MA-3004 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
Medical condition: Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
